We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-4.24%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$4.4B
AUM Growth
-$1.33B
Cap. Flow
-$405M
Cap. Flow %
-9.2%
Top 10 Hldgs %
53.32%
Holding
82
New
7
Increased
5
Reduced
49
Closed
11
Avg Time Held
1.8 years
Top 10 Avg Time Held
1.7 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
SNCE
Science 37 Holdings, Inc. Common Stock
SNCE
+$220M
2
AUGX icon
Augmedix, Inc. Common Stock
AUGX
+$52.1M
3
TRDA icon
Entrada Therapeutics
TRDA
+$47.4M
4
CNC icon
Centene
CNC
+$26.5M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$24.6M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$100M
2
ARGX icon
argenx
ARGX
+$63.6M
3
DCPH icon
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$63.3M
4
SKIN icon
SkinHealth Systems
SKIN
+$61.9M
5
CLDX icon
Celldex Therapeutics
CLDX
+$38.3M

Sector Composition

Rank Sector Weight
1 Healthcare 96.18%
2 Consumer Staples 2.79%
3 Industrials 1.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MDVL
51
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$15.5M 0.35%
221,502
-12,993
-6% -$1.4M
2020 Q4
4 quarters
LVTX icon
52
DELISTED
LAVA Therapeutics
LVTX
$15.5M 0.35%
2,816,196
– –
2021 Q1
3 quarters
TKNO icon
53
Alpha Teknova
TKNO
$408M
$14.8M 0.34%
725,000
– –
2021 Q2
2 quarters
ZYME icon
54
Zymeworks
ZYME
$1.85B
$14.3M 0.33%
874,397
-7,700
-0.9% -$161K
2020 Q1
7 quarters
IVVD icon
55
Invivyd
IVVD
$197M
$13.9M 0.32%
1,920,960
-1,326,000
-41% -$34.5M
2021 Q3
1 quarter
JAZZ icon
56
Jazz Pharmaceuticals
JAZZ
$13.9B
$12.5M 0.28%
98,064
-763,337
-89% -$100M
2021 Q1
3 quarters
KLRS icon
57
Kalaris Therapeutics
KLRS
$52.1M
$10.7M 0.24%
35,799
-588
-2% -$273K
2020 Q3
5 quarters
STXS icon
58
Stereotaxis
STXS
$105M
$10.5M 0.24%
1,698,204
-157,300
-8% -$940K
2019 Q3
9 quarters
ACHL
59
DELISTED
Achilles Therapeutics
ACHL
$10.5M 0.24%
2,088,089
– –
2021 Q1
3 quarters
NGM
60
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$10.3M 0.23%
582,805
-1,922,313
-77% -$36.9M
2021 Q1
3 quarters
RCEL icon
61
Avita Medical
RCEL
$415M
$8.05M 0.18%
672,411
-673,806
-50% -$10.3M
2020 Q3
5 quarters
DCPH icon
62
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$6.5M 0.15%
664,817
-3,366,704
-84% -$63.3M
2017 Q3
17 quarters
TCRR
63
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$6.27M 0.14%
1,346,058
-2,470,651
-65% -$15.4M
2019 Q1
11 quarters
AYLA
64
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$5.68M 0.13%
667,816
– –
2020 Q2
6 quarters
HOOK icon
65
DELISTED
HOOKIPA Pharma
HOOK
$5.56M 0.13%
238,514
+54,083
+29% +$2.17M
2019 Q2
10 quarters
XERS icon
66
Xeris Biopharma Holdings
XERS
$1.84B
$3.07M 0.07%
1,046,587
-312,238
-23% -$674K
2018 Q2
14 quarters
CTSO icon
67
Cytosorbents Corp
CTSO
$9.64M
$3M 0.07%
35,862
-16,360
-31% -$1.84M
2020 Q3
5 quarters
SONX
68
DELISTED
Sonendo, Inc.
SONX
$2.87M 0.07%
+498,131
New +$4.48M
2021 Q4
0 quarters
CABA icon
69
Cabaletta Bio
CABA
$263M
$2.64M 0.06%
696,377
– –
2019 Q4
8 quarters
BCEL
70
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$2.42M 0.06%
800,306
-369,700
-32% -$1.73M
2019 Q2
10 quarters
EPZM
71
DELISTED
Epizyme, Inc
EPZM
$1.14M 0.03%
454,475
-7,004,185
-94% -$27.5M
2017 Q3
17 quarters
AMED icon
72
DELISTED
Amedisys
AMED
– –
-150,376
Closed -$22.4M –
APRE icon
73
Aprea Therapeutics
APRE
$7.78M
– –
-34,746
Closed -$3.55M –
LFST icon
74
Lifestance Health
LFST
$4.7B
– –
-1,222,408
Closed -$17.7M –
OVID icon
75
Ovid Therapeutics
OVID
$441M
– –
-40,674
Closed -$137K –
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2021 Portfolio in Review

As of Q4 2021, Redmile Group held 82 positions worth $4.4B, down 23% from $5.73B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Redmile Group withdrew a net $405M in Q4 2021, closing 11 positions and reducing 49 holdings. Its most notable exit was Amedisys, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Redmile Group opened a new position in Science 37 Holdings, Inc. Common Stock worth $247M.

  • Redmile Group's largest Q4 2021 buy was Science 37 Holdings, Inc. Common Stock: 990,412 shares worth $247M.
  • Redmile Group added most to Amicus Therapeutics in Q4 2021, an estimated $21.4M increase.
  • Redmile Group's biggest Q4 2021 reduction was Jazz Pharmaceuticals, cutting an estimated $100M.
  • Redmile Group fully exited Amedisys in Q4 2021, selling an estimated $22.4M.
  • Redmile Group's ten largest holdings make up 53% of its $4.4B portfolio in Q4 2021.
  • Redmile Group opened 7 new positions and closed 11 in Q4 2021.
  • Redmile Group's portfolio value fell 23% quarter-over-quarter to $4.4B.

Based on Redmile Group's 13F filing for Q4 2021, filed 14 Feb 2022.